A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy

Angela C. Hirbe, Vanessa Eulo, Chang In Moon, Jingqin Luo, Stephanie Myles, ­Mahesh Seetharam, Jacqui Toeniskoetter, Tammy Kershner, Sasha Haarberg, Mark Agulnik, Varun Monga, Mohammed Milhem, Amanda Parkes, Steven I. Robinson, Scott H. Okuno, Steven Attia, Brian Andrew Van Tine